![]() | Only 14 pages are availabe for public view |
Abstract Vitiligo is a common depigmenting skin disorder characterized by acquired, idiopathic, progressive, circumscribed milky white patches of the skin and mucosa. It is characterized histologically by absence of functional melanocytes in the affected area (1). Vitiligo reduces patient’s quality of life and produce an important psychosocial burden despite of modern advances in medical science.(2) Although the treatment modalities of vitiligo have been improved, therapy is still not satisfying for many patients. This is probably due to the fact that the pathogenesis is not yet fully understood, but researchers suggest that it may arise from autoimmune, genetic, oxidative stress, neural, or viral causes.(3). Vitiligo causes partial or total destruction of melanocytes, that starts at the epidermis and later even at the hair follicles (HFs) known as leukotrichia Repigmentation can be achieved by either activating the existing melanocyte reservoir or providing a melanocyte reservoir as a source for pigmentation (2). This forms the underlying principle for various treatment modalities available today (4). |